Should I buy or sell Indaptus Therapeutics stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Indaptus Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" INDP shares. View INDP analyst ratings or view top-rated stocks .

What is Indaptus Therapeutics' stock price target for 2024?

1 Wall Street research analysts have issued twelve-month price targets for Indaptus Therapeutics' shares. Their INDP share price targets range from $12.00 to $12.00. On average, they anticipate the company's share price to reach $12.00 in the next year. This suggests a possible upside of 376.2% from the stock's current price. View analysts price targets for INDP or view top-rated stocks among Wall Street analysts .

How have INDP shares performed in 2024?

Indaptus Therapeutics' stock was trading at $1.76 on January 1st, 2024. Since then, INDP stock has increased by 43.2% and is now trading at $2.52. View the best growth stocks for 2024 here .

When is Indaptus Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our INDP earnings forecast .

How were Indaptus Therapeutics' earnings last quarter?

Indaptus Therapeutics, Inc. (NASDAQ:INDP) announced its earnings results on Wednesday, March, 13th. The company reported ($0.47) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.54) by $0.07.

How do I buy shares of Indaptus Therapeutics?

Shares of INDP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:INDP

Indaptus Therapeutics (INDP) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Free INDP Stock Alerts

$2.52

-0.14 (-5.26%)

(As of 04/18/2024 ET)

Compare

Today's Range: $2.45
▼
$2.63
50-Day Range: $1.63
▼
$2.77
52-Week Range: $1.56
▼
$4.08

Volume: 27,003 shs
Average Volume: 73,455 shs
Market Capitalization: $21.52 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $12.00

Get Indaptus Therapeutics alerts:

Indaptus Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 376.2% Upside
$12.00 Price Target
Short Interest: Healthy
1.71% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.15
Based on 12 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($1.83) to ($1.44) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.21 out of 5 stars

Medical Sector

519th out of 918 stocks

Pharmaceutical Preparations Industry

225th out of 402 stocks

3.5

Analyst's Opinion

Consensus Rating
Indaptus Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Indaptus Therapeutics has only been the subject of 1 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
1.71% of the float of Indaptus Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Indaptus Therapeutics has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Indaptus Therapeutics has recently increased by 0.70%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Indaptus Therapeutics does not currently pay a dividend.
Dividend Growth
Indaptus Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for INDP.

2.3

News and Social Media Coverage

News Sentiment
Indaptus Therapeutics has a news sentiment score of 0.15. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.49 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 12 news articles for Indaptus Therapeutics this week, compared to 1 article on an average week.
Search Interest
5 people have searched for INDP on MarketBeat in the last 30 days.
MarketBeat Follows
Only 1 people have added Indaptus Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Indaptus Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
27.10% of the stock of Indaptus Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 7.06% of the stock of Indaptus Therapeutics is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Indaptus Therapeutics are expected to grow in the coming year, from ($1.83) to ($1.44) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Indaptus Therapeutics is -1.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Indaptus Therapeutics is -1.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Indaptus Therapeutics has a P/B Ratio of 1.75. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

About Indaptus Therapeutics Stock (NASDAQ:INDP)

Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York.

INDP Stock Price History

30 days | 90 days | 365 days | Advanced Chart

INDP Stock News Headlines

April 18, 2024 | americanbankingnews.com

HC Wainwright Analysts Cut Earnings Estimates for Indaptus Therapeutics, Inc. (NASDAQ:INDP)

April 17, 2024 | americanbankingnews.com

Indaptus Therapeutics, Inc. (NASDAQ:INDP) to Post Q1 2025 Earnings of ($0.38) Per Share, HC Wainwright Forecasts

April 18, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

April 16, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Indaptus Therapeutics Amidst Promising Clinical Advances and Potential Market Impact

April 16, 2024 | americanbankingnews.com

Indaptus Therapeutics' (INDP) Buy Rating Reaffirmed at HC Wainwright

April 12, 2024 | investing.com

Indaptus reveals immune-boosting cancer therapy data

April 12, 2024 | markets.businessinsider.com

Buy Rating for Indaptus Therapeutics: Promising Oncology Breakthrough with Decoy20 Platform

April 11, 2024 | globenewswire.com

Indaptus Therapeutics Presents Positive Mechanism of Action Data at the American Association for Cancer Research Annual Meeting

April 18, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

March 28, 2024 | msn.com

Armaguard rebuffs $26m cash lifeline

March 28, 2024 | finance.yahoo.com

Indaptus Therapeutics to Present at the MedInvest Biotech and Pharma Investor Conference

March 25, 2024 | globenewswire.com

Indaptus Therapeutics Previews Positive Mechanism of Action Data to be Presented at the American Association for Cancer Research Annual Meeting

March 18, 2024 | finance.yahoo.com

Indaptus Therapeutics to Participate in Tribe Public Webinar On Wednesday, March 20, 2024

March 13, 2024 | msn.com

Indaptus Dives on Quarterly Results

March 13, 2024 | benzinga.com

Indaptus Therapeutics: Q4 Earnings Insights

March 13, 2024 | globenewswire.com

Indaptus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update

March 4, 2024 | markets.businessinsider.com

Indaptus Reports Positive Decoy20 Results, To Advance To Multi-dosing; Stock Up In Pre-market

March 4, 2024 | globenewswire.com

Indaptus Therapeutics Announces Positive Results from Second Cohort of Phase 1 Trial; Company Initiates Multi-Dose Cohort

March 4, 2024 | globenewswire.com

Indaptus Therapeutics Announces Positive Results from Second Cohort of Phase 1 Trial; Company Initiates Multi-Dose Cohort

February 25, 2024 | benzinga.com

Indaptus Therapeutics Stock (NASDAQ:INDP) Insider Trades

February 15, 2024 | finance.yahoo.com

Indaptus Therapeutics to Present at the 2024 BIO CEO & Investor Conference

February 8, 2024 | finance.yahoo.com

Indaptus Therapeutics Expands Digital Presence with Launch of Social Media Channels

January 4, 2024 | finance.yahoo.com

European Patent Office Approves Key Patent for Indaptus Therapeutics’ Platform Technology

December 22, 2023 | finance.yahoo.com

Indaptus Therapeutics, Inc. (INDP) stock forecast and price target

November 27, 2023 | msn.com

Indaptus Therapeutics (INDP) Price Target Increased by 25.00% to 10.20

November 7, 2023 | markets.businessinsider.com

Analysts Conflicted on These Healthcare Names: Ventyx Biosciences (VTYX) and Indaptus Therapeutics (INDP)

November 6, 2023 | msn.com

Indaptus Therapeutics GAAP EPS of -$0.47 beats by $0.05

See More Headlines

Receive INDP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Indaptus Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/13/2024
Today: 4/18/2024
Next Earnings (Estimated): 5/09/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:INDP
CUSIP: N/A
CIK: 1857044
Web: intecpharma.com
Phone: (646) 427-2727
Fax: 972-2586-9176
Employees: 7
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $12.00
High Stock Price Target: $12.00
Low Stock Price Target: $12.00
Potential Upside/Downside: +356.3%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.84)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-15,420,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -91.78%
Return on Assets: -80.42%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 5.05
Quick Ratio: 5.05

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.44 per share
Price / Book: 1.83

Miscellaneous

Outstanding Shares: 8,540,000
Free Float: 6,225,000
Market Cap: $22.46 million
Optionable: Not Optionable
Beta: 1.28

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

Key Executives

Mr. Jeffrey A. Meckler (Age 57)
CEO & Director
Comp: $888.32k
Mr. Walt Addison Linscott Esq. (Age 63)
Chief Operating Officer
Comp: $666.63k
Dr. Michael J. Newman Ph.D. (Age 67)
Founder, Chief Scientific Officer & Director
Comp: $468.82k
Mr. Nir Sassi (Age 48)
CFO, Secretary & Treasurer
Comp: $378.47k
Dr. Roger J. Waltzman M.B.A. (Age 55)
M.D., Chief Medical Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

INDP Stock Analysis - Frequently Asked Questions

Should I buy or sell Indaptus Therapeutics stock right now?: 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Indaptus Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" INDP shares.
View INDP analyst ratings or view top-rated stocks.
What is Indaptus Therapeutics' stock price target for 2024?: 1 Wall Street research analysts have issued twelve-month price targets for Indaptus Therapeutics' shares. Their INDP share price targets range from $12.00 to $12.00. On average, they anticipate the company's share price to reach $12.00 in the next year. This suggests a possible upside of 376.2% from the stock's current price.
View analysts price targets for INDP or view top-rated stocks among Wall Street analysts.
How have INDP shares performed in 2024?: Indaptus Therapeutics' stock was trading at $1.76 on January 1st, 2024. Since then, INDP stock has increased by 43.2% and is now trading at $2.52.
View the best growth stocks for 2024 here.
When is Indaptus Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our INDP earnings forecast.

How were Indaptus Therapeutics' earnings last quarter?: Indaptus Therapeutics, Inc. (NASDAQ:INDP) announced its earnings results on Wednesday, March, 13th. The company reported ($0.47) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.54) by $0.07.
How do I buy shares of Indaptus Therapeutics?: Shares of INDP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:INDP) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Indaptus Therapeutics (INDP) Stock Price, News & Analysis

Indaptus Therapeutics MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Indaptus Therapeutics Stock (NASDAQ:INDP)

INDP Stock Price History

INDP Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

INDP Stock Analysis - Frequently Asked Questions

Overall MarketRank^™